Exabis Library
Welcome to the e-CCO Library!
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP001: European Crohn's and Colitis Organisation topical review on environmental factors in IBD
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn’s disease patients
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn’s disease by serum protein analysis: results from the UNITI-1 and UNITI-2 Phase 3 induction studies
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP002: Trends in small bowel resections for Crohn's disease with and without short bowel syndrome in the era of biologics
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric ulcerative colitis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP003: Proximal disease extension in patients with limited ulcerative colitis: a Danish population-based inception cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP004: Epigenetic control of colonic epithelial antigen processing, barrier function, and the microbiome via methyl-CpG binding domain protein 2
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP004: Ethnicity and country of birth are associated with phenotypic differences in patients with inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP005: A role for IL1 in mediating intestinal inflammation in IL10 receptor deficiency in mice and humans
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP005: Proximal disease extension in limited ulcerative colitis: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP006: Gut-homing adipose tissue T-cells might influence intestinal barrier function in Crohn’s disease and obesity
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP006: Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by ECCO
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP007: Crohn's disease exclusion diet and partial enteral nutrition (CDED+PEN) vs exclusive enteral nutrition (EEN). Microbiome changes of a randomized clinical trial (RCT) in pediatric CD: remission is associated with similar structural + functional profiles
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM